Sabby Management’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Sabby Management’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-10,815	Closed	-$79K	–	203
2021 Q1	$79K	Sell	10,815 -57,277	-84%	-$494K	0.02%	148
2020 Q4	$393K	Buy	68,092 +42,053	+162%	+$241K	0.08%	70
2020 Q3	$155K	Sell	26,039 -61,280	-70%	-$303K	0.02%	106
2020 Q2	$450K	Sell	87,319 -24,836	-22%	-$157K	0.09%	59
2020 Q1	$406K	Buy	+112,155	New	+$557K	0.17%	42
2019 Q3	–	Sell	-28,111	Closed	-$209K	–	116
2019 Q2	$189K	Buy	+28,111	New	+$241K	0.24%	59
2017 Q2	–	Sell	-86,890	Closed	-$513K	–	285
2017 Q1	$513K	Buy	+86,890	New	+$628K	0.03%	177
2014 Q2	–	Sell	-57,342	Closed	-$857K	–	299
2014 Q1	$857K	Sell	57,342 -91,670	-62%	-$1.65M	0.05%	146
2013 Q4	$2.74M	Buy	+149,012	New	+$2.98M	0.17%	66

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.87B AUM 46.92% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Sabby Management's AVEO Position: Q2 2021 in Review

Sabby Management sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q2 2021, closing a stake of 10,815 shares — an estimated $79K sold.

Sabby Management first reported a position in AVEO in Q4 2013 and held it in 9 quarters. The position peaked at $2.74M in Q4 2013. 64 funds tracked by Wall St. Rank hold AVEO as of Q2 2021.

Sabby Management reported no remaining AVEO Pharmaceuticals, Inc. position as of Q2 2021 after selling out during the quarter.
Sabby Management sold 10,815 AVEO Pharmaceuticals, Inc. shares in Q2 2021, an estimated $79K.
Sabby Management first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2013 and held it in 9 quarters.
Sabby Management's AVEO Pharmaceuticals, Inc. position peaked at $2.74M in Q4 2013.
64 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q2 2021.

Based on Sabby Management's 13F filing for Q2 2021, filed 16 Aug 2021.